{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T04:25:08Z","timestamp":1759638308333,"version":"3.44.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T00:00:00Z","timestamp":1694736000000},"content-version":"am","delay-in-days":318,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000874","name":"Brain and Behavior Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000874","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009670","name":"National Alliance for Research on Schizophrenia and Depression","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009670","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01-DA041454"],"award-info":[{"award-number":["R01-DA041454"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.neuropharm.2022.109221","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T02:33:50Z","timestamp":1662518030000},"page":"109221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Allosteric modulators of the \u03b4 GABAA receptor subtype demonstrate a therapeutic effect in morphine-antinociceptive tolerance and withdrawal in mice"],"prefix":"10.1016","volume":"219","author":[{"given":"K.","family":"Genaro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.F.","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.P.","family":"Doan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.B.","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Hogenkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.W.","family":"Gee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41386-018-0127-4","article-title":"Neuronal and glia factors contributing to sex differences in opioid modulation of pain","volume":"44","author":"Averitt","year":"2019","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/bja\/aet127","article-title":"Sex differences in pain: a brief review of clinical and experimental findings","volume":"111","author":"Bartley","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2022.109221_bib3","article-title":"Realizing the therapeutic potential of neuroactive steroid modulators of the GABAA receptor","volume":"12","author":"Belelli","year":"2019","journal-title":"Neurobiol. Stress"},{"issue":"11","key":"10.1016\/j.neuropharm.2022.109221_bib4","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1210\/en.2013-1420","article-title":"Synergy: a concept in search of a definition","volume":"154","author":"Berthoud","year":"2013","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.neuropharm.2022.109221_bib6","doi-asserted-by":"crossref","first-page":"626","DOI":"10.3389\/fpsyt.2019.00626","article-title":"Molecular imaging of opioid and dopamine systems: insights into the pharmacogenetics of opioid use disorders","volume":"10","author":"Burns","year":"2019","journal-title":"Front. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib7","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36511-5","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3\u03b1-Hydroxy-3\u03b2-methyl-5\u03b1-pregnan-20-one), a selective, high-affinity, steroid modulator of the \u03b3-aminobutyric AcidA receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib8","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1124\/jpet.115.229302","article-title":"Neurosteroid structure-activity relationships for functional activation of extrasynaptic \u03b4GABA(A) receptors","volume":"357","author":"Carver","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109221_bib9","doi-asserted-by":"crossref","first-page":"116","DOI":"10.3389\/fphar.2014.00116","article-title":"It's MORe exciting than mu: crosstalk between mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system","volume":"5","author":"Chartoff","year":"2014","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2022.109221_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.apha.2017.03.003","article-title":"GABAA receptors and the diversity in their structure and pharmacology","volume":"79","author":"Chua","year":"2017","journal-title":"Adv. Pharmacol."},{"issue":"18","key":"10.1016\/j.neuropharm.2022.109221_bib11","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/0024-3205(83)90103-0","article-title":"Naloxone hyperalgesia and stress-induced analgesia in rats","volume":"32","author":"Coderre","year":"1983","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib12","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00213-005-0111-7","article-title":"Neurosteroids in nicotine and morphine dependence","volume":"186","author":"Concas","year":"2006","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2022.109221_bib13","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev-neuro-080317-061522","article-title":"Endogenous and exogenous opioids in pain","volume":"8","author":"Corder","year":"2018","journal-title":"Annu. Rev. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00002508-200305000-00005","article-title":"Sex differences in opioid analgesia: \"from mouse to man","volume":"19","author":"Craft","year":"2003","journal-title":"Clin. J. Pain"},{"key":"10.1016\/j.neuropharm.2022.109221_bib15","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1038\/s41598-019-44286-0","article-title":"Female-specific decreases in alcohol binge-like drinking resulting from GABAA receptor delta-subunit knockdown in the VTA","volume":"9","author":"Darnieder","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2022.109221_bib16","series-title":"Hormones, Brain and Behavior","first-page":"137","article-title":"64 - anatomy, development, and function of sexually dimorphic neural circuits in the mammalian brain","author":"de Vries","year":"2002"},{"key":"10.1016\/j.neuropharm.2022.109221_bib17","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00429-014-0717-9","article-title":"A mu\u2013delta opioid receptor brain atlas reveals neuronal co-occurrence in subcortical networks","volume":"220","author":"Erbs","year":"2015","journal-title":"Brain Struct. Funct."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109221_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.tins.2015.01.002","article-title":"Understanding opioid reward","volume":"38","author":"Fields","year":"2015","journal-title":"Trends Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib19","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"year":"2019","series-title":"Prevalence of Prescription Opioid Analgesic Use Among Adults: United States, 2013\u20132016","author":"Frenk","key":"10.1016\/j.neuropharm.2022.109221_bib20"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib21","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cne.903590111","article-title":"GABAA-receptor heterogeneity in the adult rat brain: differential regional and cellular distribution of seven major subunits","volume":"359","author":"Fritschy","year":"1995","journal-title":"J. Comp. Neurol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib22","doi-asserted-by":"crossref","first-page":"E237","DOI":"10.1152\/ajpendo.00308.2012","article-title":"Understanding synergy","volume":"304","author":"Geary","year":"2013","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib23","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1124\/jpet.109.161885","article-title":"Limiting activity at beta1-subunit-containing GABAA receptor subtypes reduces ataxia","volume":"332","author":"Gee","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109221_bib24","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1111\/j.1526-4637.2009.00663.x","article-title":"Prevention and reversal of morphine tolerance by the analgesic neuroactive steroid alphadolone","volume":"10","author":"Goodchild","year":"2009","journal-title":"Pain Med."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109221_bib25","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"Greco","year":"1995","journal-title":"Pharmacol. Rev."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109221_bib26","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.neuropharm.2010.12.030","article-title":"GABA and central neuropathic pain following spinal cord injury","volume":"60","author":"Gwak","year":"2011","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2016.18.1\/shaber","article-title":"Corticostriatal circuitry","volume":"18","author":"Haber","year":"2016","journal-title":"Dialogues Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib28","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0028-3908(03)00187-4","article-title":"The modulatory effects of the anxiolytic etifoxine on GABA(A) receptors are mediated by the beta subunit","volume":"45","author":"Hamon","year":"2003","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109221_bib29","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0022-3565(25)26704-0","article-title":"Some narcotic antagonists in the BENZOMORPHAN series","volume":"143","author":"Harris","year":"1964","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2022.109221_bib30","series-title":"Poster Presented at the 2019 NIH CounterACT Network Research Symposium, New York, NY, USA","article-title":"Modulators of extrasynaptic \u03b14\u03b23\u03b4 GABAA receptors reverse electrographic status epilepticus in the rat after acute organophosphorus poisoning","author":"Hogenkamp","year":"2019"},{"issue":"17","key":"10.1016\/j.neuropharm.2022.109221_bib31","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1007\/s00213-014-3494-5","article-title":"Pharmacological profile of a 17\u03b2-heteroaryl-substituted neuroactive steroid","volume":"231","author":"Hogenkamp","year":"2014","journal-title":"Psychopharmacology (Berl)"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib32","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1007688817873","article-title":"Do antiepileptics phenytoin, carbamazepine, and loreclezole show GABA(A) receptor subtype selectivity in rat brain sections?","volume":"26","author":"Holopainen","year":"2001","journal-title":"Neurochem. Res."},{"issue":"23","key":"10.1016\/j.neuropharm.2022.109221_bib33","doi-asserted-by":"crossref","first-page":"6321","DOI":"10.1523\/JNEUROSCI.0646-16.2016","article-title":"mir-500-Mediated GAD67 downregulation contributes to neuropathic pain","volume":"36","author":"Huang","year":"2016","journal-title":"J. Neurosci."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109221_bib34","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1002\/ejp.891","article-title":"Reductions in tonic GABAergic current in substantia gelatinosa neurons and GABAA receptor \u03b4 subunit expression after chronic constriction injury of the sciatic nerve in mice","volume":"20","author":"Iura","year":"2016","journal-title":"Eur. J. Pain"},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib35","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/j.pain.0000000000001392","article-title":"Positive allosteric modulation of non-benzodiazepine \u03b3-aminobutyric acidA receptor subtypes for the treatment of chronic pain","volume":"160","author":"Johnstone","year":"2019","journal-title":"Pain"},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109221_bib36","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1097\/00001756-200008210-00004","article-title":"Opioid- and GABA(A)-receptors are co-expressed by neurons in rat brain","volume":"11","author":"Kalyuzhny","year":"2000","journal-title":"Neuroreport"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109221_bib37","doi-asserted-by":"crossref","first-page":"147","DOI":"10.5625\/lar.2018.34.4.147","article-title":"Mouse Cre-LoxP system: general principles to determine tissue-specific roles of target genes","volume":"34","author":"Kim","year":"2018","journal-title":"Lab. Anim. Res."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib38","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.biopsych.2019.05.023","article-title":"Neurobiology of opioid addiction: opponent process, hyperkatifeia, and negative reinforcement","volume":"87","author":"Koob","year":"2020","journal-title":"Biol. Psychiatr."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109221_bib39","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0893-133X(00)00195-0","article-title":"Drug addiction, dysregulation of reward, and allostasis","volume":"24","author":"Koob","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2022.109221_bib40","first-page":"433","article-title":"Neurosteroids: a new class of neuromodulators","volume":"31","author":"Kulkarni","year":"1995","journal-title":"Drugs Today"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib41","article-title":"The impact of tonic GABAA receptor-mediated inhibition on neuronal excitability varies across brain region and cell type","volume":"8","author":"Lee","year":"2014","journal-title":"Front. Neural Circ."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109221_bib42","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nbt.1549","article-title":"Synergistic drug combinations tend to improve therapeutically relevant selectivity","volume":"27","author":"Leh\u00e1r","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.neuropharm.2022.109221_bib43","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/npp.2016.12","article-title":"Mu opioid receptor modulation of dopamine neurons in the periaqueductal gray\/dorsal raphe: a role in regulation of pain","volume":"41","author":"Li","year":"2016","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"10.1016\/j.neuropharm.2022.109221_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/kjm2.12088","article-title":"Voltage-gated sodium channel 1.7 expression decreases in dorsal root ganglia in a spinal nerve ligation neuropathic pain model","volume":"35","author":"Li","year":"2019","journal-title":"Kaohsiung J. Med. Sci."},{"key":"10.1016\/j.neuropharm.2022.109221_bib45","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fnmol.2020.00006","article-title":"Lack of neurosteroid selectivity at \u03b4 vs. \u03b32-containing GABAA receptors in dentate granule neurons","volume":"13","author":"Lu","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109221_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108675","article-title":"Delta-containing GABAA receptors in pain management: promising targets for novel analgesics","volume":"195","author":"Luo","year":"2021","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109221_bib47","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1523\/JNEUROSCI.4634-09.2010","article-title":"micro-Opioid receptor endocytosis prevents adaptations in ventral tegmental area GABA transmission induced during naloxone-precipitated morphine withdrawal","volume":"30","author":"Madhavan","year":"2010","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109221_bib48","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMra1800222","article-title":"Opioid tolerance in critical illness","volume":"380","author":"Martyn","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.neuropharm.2022.109221_bib49","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/j.neuron.2014.04.030","article-title":"Separate GABA afferents to dopamine neurons mediate acute action of opioids, development of tolerance, and expression of withdrawal","volume":"82","author":"Matsui","year":"2014","journal-title":"Neuron"},{"issue":"4","key":"10.1016\/j.neuropharm.2022.109221_bib50","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1089\/neu.2009.1166","article-title":"Loss of GABAergic interneurons in laminae I-III of the spinal cord dorsal horn contributes to reduced GABAergic tone and neuropathic pain after spinal cord injury","volume":"27","author":"Meisner","year":"2010","journal-title":"J. Neurotrauma"},{"issue":"22","key":"10.1016\/j.neuropharm.2022.109221_bib51","doi-asserted-by":"crossref","first-page":"12905","DOI":"10.1073\/pnas.96.22.12905","article-title":"Attenuated sensitivity to neuroactive steroids in gamma-aminobutyrate type A receptor delta subunit knockout mice","volume":"96","author":"Mihalek","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"10.1016\/j.neuropharm.2022.109221_bib52","first-page":"1708","article-title":"GABA(A)-receptor delta subunit knockout mice have multiple defects in behavioral responses to ethanol","volume":"25","author":"Mihalek","year":"2001","journal-title":"Alcohol Clin. Exp. Res."},{"key":"10.1016\/j.neuropharm.2022.109221_bib53","article-title":"Pain management with opioids in adults","author":"Montgomery","year":"2020","journal-title":"J. Neurosci. Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2022.109221_bib54","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1526-968X(200002)26:2<99::AID-GENE1>3.0.CO;2-B","article-title":"Cre recombinase: the universal reagent for genome tailoring","volume":"26","author":"Nagy","year":"2000","journal-title":"Genesis"},{"issue":"19","key":"10.1016\/j.neuropharm.2022.109221_bib55","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1073\/pnas.0701321104","article-title":"Nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators","volume":"104","author":"Ng","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109221_bib56","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2147\/NDT.S200568","article-title":"An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action","volume":"15","author":"Nuss","year":"2019","journal-title":"Neuropsychiatric Dis. Treat."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0014-2999(97)01294-6","article-title":"Chronic neurosteroid treatment prevents the development of morphine tolerance and attenuates abstinence behavior in mice","volume":"337","author":"Reddy","year":"1997","journal-title":"Eur. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib58","article-title":"Mu opioid receptors on vGluT2-expressing glutamatergic neurons modulate opioid reward. Addict","volume":"26","author":"Reeves","year":"2021","journal-title":"Biol."},{"issue":"1","key":"10.1016\/j.neuropharm.2022.109221_bib59","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2174\/1871527311312010017","article-title":"Opioid withdrawal syndrome: emerging concepts and novel therapeutic targets","volume":"12","author":"Rehni","year":"2013","journal-title":"CNS Neurol. Disord.: Drug Targets"},{"key":"10.1016\/j.neuropharm.2022.109221_bib60","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fphar.2017.00158","article-title":"An introduction to terminology and methodology of chemical synergy-perspectives from across disciplines","volume":"8","author":"Roell","year":"2017","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.neuropharm.2022.109221_bib61","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0166-2236(99)01399-5","article-title":"Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives","volume":"22","author":"Rupprecht","year":"1999","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2022.109221_bib62","first-page":"1419","article-title":"Drug and opioid-involved overdose deaths \u2014 United States, 2013\u20132017","volume":"67","author":"Scholl","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"24","key":"10.1016\/j.neuropharm.2022.109221_bib63","doi-asserted-by":"crossref","first-page":"5080","DOI":"10.1093\/nar\/23.24.5080","article-title":"A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells","volume":"23","author":"Schwenk","year":"1995","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.neuropharm.2022.109221_bib64","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1017\/S1461145712001071","article-title":"Reduced LTP and LTD in prefrontal cortex synapses in the nucleus accumbens after heroin self-administration","volume":"16","author":"Shen","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"48","key":"10.1016\/j.neuropharm.2022.109221_bib65","doi-asserted-by":"crossref","first-page":"40224","DOI":"10.1074\/jbc.R112.386664","article-title":"Structure, function, and modulation of GABA(A) receptors","volume":"287","author":"Sigel","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"24","key":"10.1016\/j.neuropharm.2022.109221_bib66","doi-asserted-by":"crossref","first-page":"14439","DOI":"10.1073\/pnas.2435457100","article-title":"Neuroactive steroids reduce neuronal excitability by selectively enhancing tonic inhibition mediated by delta subunit-containing GABAA receptors","volume":"100","author":"Stell","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7","key":"10.1016\/j.neuropharm.2022.109221_bib67","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1523\/JNEUROSCI.17-07-02585.1997","article-title":"mu-Opioid receptors are localized to extrasynaptic plasma membranes of GABAergic neurons and their targets in the rat nucleus accumbens","volume":"17","author":"Svingos","year":"1997","journal-title":"J. Neurosci."},{"issue":"13","key":"10.1016\/j.neuropharm.2022.109221_bib68","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/s41386-018-0225-3","article-title":"Untangling the complexity of opioid receptor function","volume":"43","author":"Valentino","year":"2018","journal-title":"Neuropsychopharmacology"},{"issue":"6660","key":"10.1016\/j.neuropharm.2022.109221_bib69","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/37610","article-title":"How opioids inhibit GABA-mediated neurotransmission","volume":"390","author":"Vaughan","year":"1997","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib70","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/cne.22212","article-title":"Differential localization of gamma-aminobutyric acid type A and glycine receptor subunits and gephyrin in the human pons, medulla oblongata and uppermost cervical segment of the spinal cord: an immunohistochemical study","volume":"518","author":"Waldvogel","year":"2010","journal-title":"J. Comp. Neurol."},{"issue":"10","key":"10.1016\/j.neuropharm.2022.109221_bib71","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1073\/pnas.91.10.4569","article-title":"The modulatory action of loreclezole at the gamma-aminobutyric acid type A receptor is determined by a single amino acid in the beta 2 and beta 3 subunit","volume":"91","author":"Wingrove","year":"1994","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.neuropharm.2022.109221_bib72","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1213\/01.ANE.0000075835.73967.F3","article-title":"Antinociceptive properties of neurosteroids: a comparison of alphadolone and alphaxalone in potentiation of opioid antinociception","volume":"97","author":"Winter","year":"2003","journal-title":"Anesth. Analg."},{"issue":"3","key":"10.1016\/j.neuropharm.2022.109221_bib73","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1523\/JNEUROSCI.12-03-01040.1992","article-title":"The distribution of 13 GABAA receptor subunit mRNAs in the rat brain. I. Telencephalon, diencephalon, mesencephalon","volume":"12","author":"Wisden","year":"1992","journal-title":"J. Neurosci."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2022.109221_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0149-7634(89)80021-1","article-title":"Opiate reward: sites and substrates","volume":"13","author":"Wise","year":"1989","journal-title":"Neurosci. Biobehav. Rev."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390822002805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:19:46Z","timestamp":1758439186000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390822002805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":74,"alternative-id":["S0028390822002805"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109221","relation":{},"ISSN":["0028-3908"],"issn-type":[{"type":"print","value":"0028-3908"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allosteric modulators of the \u03b4 GABAA receptor subtype demonstrate a therapeutic effect in morphine-antinociceptive tolerance and withdrawal in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2022.109221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"109221"}}